BeOne Medicines Ltd. (ONC)
NASDAQ: ONC
· Real-Time Price · USD
266.77
9.26 (3.60%)
At close: Jun 24, 2025, 3:59 PM
266.80
0.01%
After-hours: Jun 24, 2025, 05:59 PM EDT
3.60% (1D)
| Bid | 265.74 |
| Market Cap | 26.51B |
| Revenue (ttm) | 4.18B |
| Net Income (ttm) | -392.37M |
| EPS (ttm) | -3.63 |
| PE Ratio (ttm) | -73.49 |
| Forward PE | 36.9 |
| Analyst | Buy |
| Ask | 266.78 |
| Volume | 410,636 |
| Avg. Volume (20D) | 443,935 |
| Open | 264.60 |
| Previous Close | 257.51 |
| Day's Range | 262.53 - 267.46 |
| 52-Week Range | 141.31 - 287.88 |
| Beta | 0.29 |
Analyst Forecast
According to 0 analyst ratings, the average rating for ONC stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
BeOne Medicines Ltd. is scheduled to release its earnings on Aug 6, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 week ago
+5.38%
BeOne Medicines shares are trading higher after th...
Unlock content with
Pro Subscription
1 month ago
-3.93%
BeiGene shares are trading lower after the company reported mixed Q1 financial results.
2 weeks ago · businesswire.com
BeOne Medicines to Host Investor R&D Day Webcast on June 26, 2025SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that it will host an Investor R&D Day in N...
2 weeks ago · seekingalpha.com
BeOne Medicines: Competitive Advantage Of Zanubrutinib In The CLL FieldZanubrutinib is currently best-in-class among BTK inhibitors for CLL, with superior efficacy and safety over ibrutinib and strong market momentum. Zanubrutinib will be in the leading position in CLL i...
